en · de · es · pt
cardarine-notes.peptides6823.com › Faq › Background And Regulatory History — Quick Reference

Background And Regulatory History — Quick Reference

By Editorial Desk · published 2026-02-14 · last reviewed 2026-03-02 · Faq

LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-03-02 and is reviewed periodically as new material appears.

Background and Regulatory History

GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.

Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.

Mechanism and Detection

Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.

GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.

Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.

Cardarine at a glance

PropertyValueNotes
Common nameCardarineCommon internet and media name.
Research codeGW501516Also written GW-1516.
Drug classPPARδ agonistNot a selective androgen receptor modulator.
Development statusDiscontinuedClinical development halted after rodent cancer findings.
Regulatory statusProhibited in sportListed by WADA; not approved as medicine.

Identity and Pharmacological Classification

PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.

Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.

Related pages on this site

Mechanism and Laboratory Detection

GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.

Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.

Supporting material

Lost Coast uses the same first-person shooter gameplay as Half-Life 2. The player is equipped with weapons from Half-Life 2, including the object-manipulating gravity gun. Like Half-Life 2, the player controls Gordon Freeman. Freeman must enter a monastery that enemy Combine are using to launch heavy artillery shells into a seaside town. The player encounters Combine soldiers and headcrabs before disabling the artillery launcher and destroying an attack helicopter with RPGs. A fisherman congratulates him and Gordon teleports away.

The spot indole test is used to determine if a microbe can deaminate tryptophan to produce indole. This test is performed by saturating a piece of filter paper with Indole Kovacs Reagent and scraping a portion of microbe onto the paper. A color to a pink-red color indicates a positive result while no color change indicates the lack of tryptophanase.

Both the new Law of Political Parties and the process of illegalization of Batasuna were strongly contested by the Basque nationalist parties and, as an alternative, the lehendakari Juan José Ibarretxe proposed a "pacification plan" based on the holding of a referendum regulating "the free association of Euskadi to the plurinational Spanish State". By the end of 2003, the tension between the central government and the "peripheral" nationalisms moved to Catalonia as a result of the formation of a left-wing "tri-party" government after the Catalan elections of November 2003 consisting of the Socialists' Party of Catalonia (PSC), Republican Left of Catalonia (ERC, a pro-independence party that had experienced a meteoric rise), and Initiative for Catalonia Greens (a party associated with United Left) and presided by the socialist Pasqual Maragall. The "Tinell Pact" of the PSC-PSOE, IC and ERC (in which the "tri-party" program was agreed, expressly excluding any agreement with the PP) was harshly criticized by the Aznar government and by the new PP leader Mariano Rajoy ─ who at the end of August 2003 had been proposed by Aznar to replace him as candidate in the following year's elections. By the end of January 2004, a scandal broke out that shook the "tri-party" government. In its 24th edition, the newspaper "ABC" published that the leader of ERC, Josep Lluís Carod Rovira, conseller en cap of the Generalitat, had met in Perpignan with the top leadership of ETA to negotiate an exclusive truce for Catalonia.

In October 2016, he was selected as a "full member" of the Royal College of Physicians of Edinburgh, one of only a handful of Turkish nationals to receive that honor, marked by a ceremony in which Okan's membership diploma was bestowed upon him by then-President of the Royal College, and later director of the National Institute for Health Research, Derek Bell. In November 2020, he was awarded an FRCP from the Royal College of Physicians of London, and in January 2021 awarded an FRCP from the Royal College of Physicians of Ireland. In his early days, he started his career as a dermatologist at Acibadem Bakirkoy Hospital and later worked Medical Park Hospital and Memorial Bahcelievler Hospital as an associate professor and also as a skin diseases specialist. He founded and chaired the Dermatology Department at Istanbul Kemerburgaz University in 2013. He volunteered with Health Volunteers Overseas as part of the Dermatology program at Preah Kossamak Hospital, Phnom Penh, Cambodia. He assisted in the training of dermatology students, provided continuing education regarding current and new trends of dermatologic diagnosis and treatment and provided training to nurses and physicians involved in dermatologic care. In 2021, Okan and his team reported their findings that psoriasis patients had unusually high levels of neurofilament and Tau protein, which act as a skeleton in the nerve cells in these patients. These levels were higher than those of non-sick individuals, especially when compared to the levels of those with severe psoriasis under the age of 40.

Cloning – Dolly the sheep was the first mammal ever cloned from adult animal cells. The cloned sheep was, of course, genetically identical to the original adult sheep. This clone was created by taking cells from the udder of a six-year-old ewe and growing them in the lab. Gene therapy – a modified or healthy gene is inserted into the organism to replace a disease-causing gene. Commonly a virus that has been altered to carry human DNA is used to deliver the healthy gene to the targeted cells of the patient. This process was first used successfully in 1990 on a four-year-old patient who lacked an immune system due to a rare genetic disease called severe combined immunodeficiency (SCID).

Sources: en.wikipedia.org

Supporting material

Symptoms of ethanol overdose may include nausea, vomiting, CNS depression, coma, acute respiratory failure, or death. Levels of even less than 0.1% can cause intoxication, with unconsciousness often occurring at 0.3–0.4%. Death from ethanol consumption is possible when blood alcohol levels reach 0.4%. A blood level of 0.5% or more is commonly fatal. The oral median lethal dose (LD50) of ethanol in rats is 5,628 mg/kg. Directly translated to human beings, this would mean that if a person who weighs 70 kg (150 lb) drank a 500 mL (17 US fl oz) glass of pure ethanol, they would have an estimated 50% risk of dying. The highest blood alcohol level ever recorded, in which the subject survived, is 1.41%.

== In vitro activity == Oritavancin shares certain properties with other members of the glycopeptide class of antibiotics, which includes vancomycin, the current standard of care for serious Gram-positive infections in the United States and Europe. It possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci. Oritavancin has potential use as a therapy for exposure to Bacillus anthracis, the Gram-positive bacterium that causes anthrax, having demonstrated efficacy in a mouse model both before and after exposure to the bacterium. Oritavancin demonstrates in vitro activity against both the planktonic and biofilmstates of staphylococci associated with prosthetic joint infection (PJI), albeit with increased minimum biofilm bactericidal concentration (MBBC) compared to Minimum inhibitory concentrations (MIC) values. Moreover oritavancin has demonstrated activity against in vitro to vancomycin-susceptible enterococci (VSE) and vancomycin-resistant enterococci (VRE) in both planktonic and biofilm states.

These lacteals drain into the thoracic duct which empties into the venous blood at the junction of the left jugular and left subclavian veins on the lower left hand side of the neck. This means that the fat-soluble products of digestion are discharged directly into the general circulation, without first passing through the liver, unlike all other digestion products. The reason for this peculiarity is unknown.

In modern everyday life there are many observations that can be successfully explained by application of Bernoulli's principle, even though no real fluid is entirely inviscid, and a small viscosity often has a large effect on the flow.

Sources: en.wikipedia.org

Notes from published material

University of Western Ontario (LL.D.) on May 30, 1924 University of Toronto (D.Sc.) in 1924 Queen's University (LL.D.) in 1924 University of Michigan (LL.D.) in 1924 Yale University (D.Sc.) in 1924 University of the State of New York (D.Sc.) in 1931 McGill University (D.Sc.) in 1939

== Species distribution == Hemocyanin was first discovered in Octopus vulgaris by Leon Fredericq in 1878. The presence of copper in molluscs was detected even earlier by Bartolomeo Bizio in 1833. Hemocyanins are found in the Mollusca and Arthropoda, including cephalopods and crustaceans, and utilized by some land arthropods such as the tarantula Eurypelma californicum, the emperor scorpion, and the centipede Scutigera coleoptrata. Also, larval storage proteins in many insects appear to be derived from hemocyanins.

=== Human capital === In order to benefit from the advent of digital agriculture, farmers must develop new skills. As Bronson (2018) notes, "training a rural work-force in Internet technology skills (e.g., coding) is obviously a key part of agricultural "modernization." Integration into the digital economy requires basic literacy (ability to read) and digital literacy (ability to use digital devices to improve welfare). In many instances, benefiting from digital content also requires English literacy or familiarity with another widely spoken language. Digital agriculture developers have designed ways around these barriers, such as ICTs with audio messages and extension videos in local languages. However, more investment in human capital development is needed to ensure all farmers can benefit from digital agriculture. Fostering human capital in the form of innovation also matters for the spread of digital agriculture. Some characterize digital agriculture innovation, a knowledge- and skills-intensive process, as concentrated in "Big Ag" companies and research universities. However, others describe small-scale entrepreneurs as the "heart of the action." In 2018, ag-tech innovation attracted $1.9 billion in venture capital, and the sector has grown significantly in the last 10 years. Although digital agriculture may be concentrated in a few developed countries because of "structure, institutional, and economic barriers," ag-tech startups have experienced significant growth in Africa, the Caribbean and Pacific, Asia, and Latin America as well.

Sources: en.wikipedia.org

Frequently asked questions

Is cardarine a selective androgen receptor modulator?

No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.

Why did clinical development stop?

Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.

Is cardarine approved for medical use?

No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.

How does cardarine work in the body?

It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.

Network